Skip to main content
SPRY logo

ARS Pharmaceuticals, Inc. (SPRY) Stock: Price, Forecast & Analyst Target

ARS Pharmaceuticals, Inc. (SPRY) — MoonshotScore 14/100 (Weak band), calculated Nov 18, 2026. Price $2.96 (-11.90%), as of the Nov 20, 2026 trading session; market cap $298M.

Educational signal · not a buy or sell recommendation · How to read this

$2.96 −$0.40 (-11.90%) Market Cap $298M

ARS Pharmaceuticals, Inc. · SPRY · NASDAQ

ARS Pharmaceuticals, Inc. Their lead product, Neffy, aims to provide a needle-free alternative to traditional epinephrine injections.

Price as of Nov 20, 2026

Key Statistics

14 of 100

MoonshotScore v2 · ARS Pharmaceuticals (SPRY)

Weak
Business Quality Poor (19)
Financial Safety Strained (24)
Valuation Bubble (13)
Growth Durability Shrinking (11)
Momentum Slipping (30)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.

  • EPS beat 0 of the last 4 reports
  • Altman Z -3.04 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SPRY (58 recorded, newest six shown)
RecordedScoreBand
14Weak
14Weak
14Weak
14Weak
14Weak
14Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.96
Change on the day-11.90%
52-week range$2.44 – $13.15
Market capitalisation$298M—
Shares traded on the day2.78M

Price & events

Other perspectives

Council score for ARS Pharmaceuticals (SPRY): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Negative
Growth Durability Negative
Momentum Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
ROE Negative
Gross Margin Moderate

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is ARS Pharmaceuticals (SPRY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ARS Pharmaceuticals, Inc. (SPRY) is listed on NASDAQ. It employs 198 people and is led by Donn Casale. The market values it at $298M.

2 · Latest results

What do the latest results show for ARS Pharmaceuticals (SPRY)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$33M-$51M-$0.52 (diluted)
Q4 FY2025$28M-$41M—
Q1 FY2026$23M-$61M-$0.61 (diluted)
Q2 FY2026$34M-$62M-$0.63 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ARS Pharmaceuticals (SPRY)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -3.04 · Piotroski F 2. Trailing ratios: ROA -39.5% · current ratio 3.25.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -3.04 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at ARS Pharmaceuticals (SPRY)?

Short answer · as of

Current published price targets run low $15.00 · high $15.00 · consensus $15.00 · median $15.00 against a quoted price of $2.96 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does ARS Pharmaceuticals compare with its peers?

Short answer

ARS Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Alopexx, Inc. (ALPX) Same industry, near in market value$10.02 Nov 20, 2026$148M61 5-pillar Nov 18, 2026
ARS Pharmaceuticals (SPRY) — this page$2.96$298M14

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$15.00 – $15.00
Consensus target
$15.00
Median target
$15.00

Consensus record · Captured .

Measured against a quoted price of $2.96 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 2, 2026

Transactions
17
Identified insiders
14
Purchases
0
Sales
2
Other transactions
15

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SPRY in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Third PointDan LoebQ3 20260.09%$4.31MHeld, unchanged

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about ARS Pharmaceuticals (SPRY)?

Read these with our analysis →

Investor Questions: SPRY Stock

These answers are editorial: 1 of these 9 answers is drawn from the SPRY research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SPRY?

SPRY carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is SPRY a good stock to buy?

Stock Expert AI does not rate SPRY buy, sell or hold. ARS Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SPRY stock price today?

The last price recorded for ARS Pharmaceuticals, Inc. (SPRY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SPRY price target?

The analyst consensus price target for ARS Pharmaceuticals, Inc. (SPRY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for SPRY?

The main risks for ARS Pharmaceuticals include regulatory risk, commercialization risk, and competition risk. Regulatory risk stems from the uncertainty of obtaining FDA approval for Neffy, as well as the potential for delays or unexpected requirements.

What are the key factors to evaluate for SPRY?

ARS Pharmaceuticals, Inc. (SPRY) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Not financial advice.

How frequently does SPRY data refresh on this page?

SPRY's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SPRY's recent stock price performance?

ARS Pharmaceuticals, Inc. (SPRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel needle-free epinephrine delivery system. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SPRY overvalued or undervalued right now?

ARS Pharmaceuticals, Inc. (SPRY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.